Tou Rong Chang Fu : APPOINTMENT OF EXECUTIVE DIRECTOR

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Tou Rong Chang Fu Group Limited ҳፄڗబණྠϞࠢʮ̡

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 850)

APPOINTMENT OF EXECUTIVE DIRECTOR

The Board is pleased to announce that Mr. Huang Guobiao€ර਷ᅺhas been appointed as an executive Director with effect from 8 January 2019.

APPOINTMENT OF EXECUTIVE DIRECTOR

The board (the "Board") of directors ("Directors" and each a "Director") of Tou Rong Chang Fu Group Limited (the "Company", together with its subsidiaries, the "Group") is pleased to announce that Mr. Huang Guobiao€ර਷ᅺ("Mr. Huang") has been appointed as an executive Director with effect from 8 January 2019. Set out below are the biographical details of Mr. Huang.

Mr. Huang Guobiao€ර਷ᅺ, aged 40, has extensive experience in the medicine industry.

From 2005 to 2009, Mr. Huang worked at ਷ᖹછٰಳ̏Ϟࠢʮ̡อतᖹʱʮ̡ (Guoyao Holding Hubei Co. Ltd. New Special Medicine Branch#), a company principally engaged in the trading of medicine and medical appliance, as the general manager, responsible for the overall business operation. From 2005 to 2016, Mr. Huang worked at ಳ̏อ˖݋ᔼᖹ߅Ҧ Ϟࠢʮ̡(Hubei Xinwenxing Medical Technology Co. Ltd.#), a company principally engaged in medical research and development, and investment in medical projects and companies engaged in medical market research, as the general manager, responsible for the overall business operation. Mr. Huang currently works at ಳ̏ɛ၅อ˖݋ᔼᖹϞࠢʮ̡(Hubei Renfu Xinwenxing Medicine Co. Ltd.#), a company principally engaged in the wholesale and research of medicine, as the general manager, responsible for the overall business operation.

Mr. Huang was the legal representative and an executive director of ؛ဏอ˖݋͛يᔼᖹ ҦஔϞࠢʮ̡ (Wuhen Xinwenxing Biological Medical Technology Co. Ltd.#) which was a company established in the PRC principally engaged in the research of biological and medical appliances and consultancy services, and was deregistered in November 2016 by its members due to the cessation of business. Mr. Huang was the general manager of ؛ဏΊቜᔼᖹක೯Ϟ ࠢʮ̡ (Wuhen Zhaofeng Medicine Development Co. Ltd.#) which was a company established in the PRC principally engaged in the research and development of medical appliances and healthcare products and consultancy services, and was struck off in July 2005 due to its failure to comply with annual inspection requirements. Mr. Huang confirmed that there is no wrongful act on his part leading to the above dissolution of companies and that he is not aware of any actual or potential claim has been or will be made against him as a result of the dissolution of such companies.

Mr. Huang has entered into a service agreement with the Company commencing from 8 January 2019, which is terminable by either party by giving a three-month written notice. Mr. Huang is appointed as an addition to the Board and shall hold office only until the next following annual general meeting of the Company and shall then be eligible for re-election in accordance with the articles of association of the Company. He will also be subject to retirement by rotation and re-election in accordance with the articles of association of the Company.

Pursuant to his service contract with the Company, Mr. Huang is entitled to a monthly salary of HK$38,000 as well as a discretionary bonus to be determined by the Board. The emoluments of Mr. Huang were determined by the Board with reference to his experience, duties and responsibilities, the prevailing market conditions and the recommendation from the remuneration committee of the Company.

As at the date of this announcement, Mr. Huang did not have any interest in the shares or underlying shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed above, as at the date of this announcement, Mr. Huang did not hold any directorship in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the past three years preceding the date of this announcement, nor did he hold any other position with the Company and other members of the Group or possess any other major appointments or professional qualifications.

Save as disclosed above, as at the date of this announcement, Mr. Huang did not have any relationship with any Director, senior management or substantial or controlling shareholder (as defined in the Rules (the "Listing Rules") Governing the Listing of Securities on the Stock Exchange) of the Company.

Save as disclosed above, the Board is not aware of any other matters relating to the appointment of Mr. Huang as an executive Director that need to be brought to the attention of the shareholders of the Company, and there is no information relating to Mr. Huang that is required to be disclosed pursuant to any requirements of Rule 13.51(2) of the Listing Rules.

The Board would also like to take this opportunity to welcome Mr. Huang for joining the Board.

By order of the Board

Tou Rong Chang Fu Group Limited

Wong Kwok Leung

Executive Director

Hong Kong, 8 January 2019

As at the date hereof, the Board comprises (i) five executive Directors, namely Mr. Wong Kwok Leung, Mr. Gan Xiaohua, Mr. Chen Yongsheng, Mr. Huang Guobiao and Mr. Li Zhenjun (suspended); (ii) one non-executive Director, namely Mr. Poon Wai Kong; and (ii) three independent non-executive Directors, namely Mr. Chan Shu Kin, Mr. Cheung Kwan Hung and Mr. Chiu Wai Piu.

#

The English translation of the Chinese name(s) in this announcement, where indicated, are included for information purpose only, and should not be regarded as the official English name(s) of such Chinese names.